When was Xeris Pharmaceuticals founded?

Xeris Pharmaceuticals was founded in 2005 and raised its 1st funding round within a year of its incorporation.

Where is Xeris Pharmaceuticals located?

Xeris Pharmaceuticals is headquartered in Chicago, United States. It is registered at Alexandria,Virginia.

How many employees does Xeris Pharmaceuticals have?

As of Sep 30, 2026, the latest employee count at Xeris Pharmaceuticals is 532.

Is Xeris Pharmaceuticals a funded company?

Xeris Pharmaceuticals is a funded company, having raised a total of $155M across 24 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 2005.

When was the latest funding round of Xeris Pharmaceuticals?

Xeris Pharmaceuticals' latest funding was a $***** Post IPO round on Jan 02, 2022, with participation from 2 investors.

What is the annual revenue of Xeris Pharmaceuticals?

Annual revenue of Xeris Pharmaceuticals is between $100M and $500M as on Dec 31, 2025

Where does Xeris Pharmaceuticals rank among its competitors?

Xeris Pharmaceuticals ranks 2nd amongst 48 active competitors, of which 9 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Pirouette Pharma, which secured $1.08M in Mar, 2026.

Who are the top competitors of Xeris Pharmaceuticals?

Xeris Pharmaceuticals' top competitors include Crossject, Companion Medical and GO-Pen. Among them, Pirouette Pharma secured the most recent funding round in March, 2026.

Xeris Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Xeris Pharmaceuticals is a public company based in Chicago (United States), founded in 2005 by Steve Prestrelski. It operates as a Developer of liquid-stable injectables for the delivery of drugs. Xeris Pharmaceuticals has raised $155M in funding from investors like Redmile Group, Central Texas Angel Network and Austin Technology Incubator. The company has 48 active competitors, including 9 funded and 5 that have exited. Its top competitors include companies like Crossject, Companion Medical and GO-Pen.

Company Details

Developer of liquid-stable injectables for the delivery of drugs. The company is developing a stable, ready-to-inject glucagon formulation "Gvoke" which is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes. The company has developed proprietary formulation technologies such as XeriSol and XeriJect which are currently being evaluated for subcutaneous and intramuscular delivery of highly-concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, and antibodies.

Website: xerispharma.com
Social
Email ID: *****@xerispharma.com
Phone Number: +1 **********
Registered Address: Alexandria,Virginia

Key Metrics

Founded Year

2005

Location

Chicago, United States

Stage

Public

Total Funding

$155M in 24 rounds

Latest Funding Round

Post IPO, Jan 02, 2022, $*****

Investors

Redmile Group & 20 more

Ranked

2^nd among 48 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

532 as on Sep 30, 2026

Investment & Acquisitions

Strongbridge Biopharma

Similar Companies

Crossject & 50 more

Exit Details

Public

View Xeris Pharmaceuticals' full profile

Xeris Pharmaceuticals is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Xeris Pharmaceuticals Inc CIN: 1346302 , United States, Active	Jul 28, 2005	$10M - $50M (As on Dec 31, 2020)	-	-
XERIS BIOPHARMA HOLDINGS, INC. CIN: 1867096 , United States, Active	May 19, 2021	$100M - $500M (As on Dec 31, 2025)	-	-
XERIS CORP. CIN: 850562995 , Belgium, Active	Dec 31, 1999	-	3 (As on Dec 31, 2021)	-
Xeris Pharmaceuticals, Inc. CIN: 203352427 , United States, Active	Dec 31, 2004	-	403 (As on Dec 31, 2024)	-

Xeris Pharmaceuticals got listed on Jun 21, 2018.

Click here to take a look at Xeris Pharmaceuticals's IPO in detail

Xeris Pharmaceuticals has raised a total funding of $155M over 24 rounds. Its first funding round was on Dec 2005. Its latest funding round was a Post IPO round on Jan 02, 2022 for $*****. 2 investors participated in its latest round. Xeris Pharmaceuticals has 21 institutional investors.

Here is the list of recent funding rounds of Xeris Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 02, 2022	1182597	Post IPO	5446865	2075602	5812988	5059041
Mar 11, 2021	3792603	Post IPO	5752737	4255667	1608879	Deerfield
Mar 08, 2018	8253497	Series C	2297553	6616525	Merieux Equity Partners	Wild Basin Investments

Access funding benchmarks and valuations. Sign up today!

View details of Xeris Pharmaceuticals's funding rounds and investors

The founders of Xeris Pharmaceuticals is Steve Prestrelski.

Here are the details of Xeris Pharmaceuticals' key team members:

Steve Prestrelski: Co-Founder & CSO of Xeris Pharmaceuticals.

View details of Xeris Pharmaceuticals's Founder profiles and Board Members

Xeris Pharmaceuticals' employee count trend

Xeris Pharmaceuticals has 532 employees as of Sep 26. Here is Xeris Pharmaceuticals's employee count trend over the years:

Employee count trend for Xeris Pharmaceuticals

Uncover Xeris Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Xeris Pharmaceuticals include Crossject, Companion Medical and GO-Pen. Here is the list of Top 10 competitors of Xeris Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Crossject 2001, Dijon (France), Public	Needle-free self-injectable drugs	$40.3M	Rothschild & Co, GSK & 5 others	60/100
2nd	Xeris Pharmaceuticals 2005, Chicago (United States), Public	Developer of liquid-stable injectables for the delivery of drugs	$155M	Armistice Capital, Longitude Capital & 19 others	60/100
3rd	Companion Medical 2013, San Diego (United States), Acquired	Medtronic Diabetes: Innovative solutions for diabetes management and insulin delivery	$19.5M	K2 HealthVentures, MedVenture Partners & 3 others	54/100
4th	GO-Pen 2019, Lyngby (Denmark), Seed	Manufacturer of reusable insulin pens with a user filled reservoir	-	Dcberne, EIC Fund & 1 others	46/100
5th	Windgap Medical 2011, Boston (United States), Series B	Provider of drug delivery autoinjector for the treatment of anaphylaxis	$76.7M	Taiwania Capital, SKK & 12 others	44/100
6th	SHL 1989, Zug (Switzerland), Funding Raised	Developer and manufacturer of autoinjectors and drug delivery system solutions	-	EQT, Athos Capital	44/100
7th	Pirouette Pharma 2021, Portsmouth (United States), Seed	Developer of auto-injector technology for injectable medicines and partner programs	$3.43M	Founders, HHS	43/100
8th	Eveon 2009, Montbonnot Saint Martin (France), Seed	Manufacture of connected medical devices focused on the preparation and administration of therapeutic treatment	$4.05M	MEDEVICE, Credit Agricole Alpes Developpement ... & 1 others	42/100
9th	MIT 1978, Montreal (Canada), Public	Provider of needleless injectors for various medical applications	-	-	36/100
10th	Qlibrium 2014, Woburn (United States), Funding Raised	Provider of on‑body drug delivery systems	-	JLABS, MassChallenge & 1 others	36/100